---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-003731"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2023-03-14T23:59:59+00:00"
generated_at: "2026-06-18T03:24:50.228991+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Editas Medicine Executive Chairman James Mullen to not seek re-election; Board adopts amended bylaws

## Summary
- James C. Mullen, Executive Chairman and former CEO, will not stand for re-election at the 2023 Annual Meeting.
- Mullen will continue as Executive Chairman until the 2023 Annual Meeting; cites best practice for former CEOs to rotate off board.
- Board approved amended and restated bylaws on March 10, 2023, conforming to recent DGCL amendments and universal proxy rules (Rule 14a-19).
- Amended bylaws require additional disclosures for stockholder nominations and allow company to disregard nominations if Rule 14a-19 requirements not met.
- Other updates include technical changes to remote meeting adjournment and stockholder list availability.

## SEC filing metadata
- accession: 0001558370-23-003731
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2023-03-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000155837023003731/0001558370-23-003731-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000155837023003731/edit-20230308x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-003731
- JSON: https://secwatch.observer/filing/0001558370-23-003731.json
- Plain text: https://secwatch.observer/filing/0001558370-23-003731.txt

## Key facts
- Executive change
  James C. Mullen departed as Executive Chairman of the Board at Editas Medicine, Inc..
  - Action: does not intend to seek re-election as a director
  - Role: Executive Chairman of the Board
  source text: On March 8, 2023, James C. Mullen, the Executive Chairman of the Board of Directors (the “Board”) of Editas Medicine, Inc. (the “Company”) notified the Board that he does not intend to seek re-election as a director of the Company when his current term ends at the 2023 Annual Meeting of Stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650664/000155837023003731/0001558370-23-003731-index.htm
- Governance Changes
  Editas Medicine, Inc.: Amended and restated bylaws to conform with recent DGCL amendments and universal proxy rules (effective 2023-03-10).
  - Change: bylaw amendment
  - Effective: 2023-03-10
  source text: On March 10, 2023, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, approved an amendment and restatement of the Amended and Restated By-Laws of the Company (as so amended and restated, the "Amended and Restated By-Laws").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650664/000155837023003731/0001558370-23-003731-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.